Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $1.6 million.

  • Agios Pharmaceuticals' Capital Expenditures rose 27112.17% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 33728.99%. This contributed to the annual value of $1.7 million for FY2024, which is 6866.87% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Capital Expenditures stood at $1.6 million for Q3 2025, which was up 27112.17% from $875000.0 recorded in Q2 2025.
  • Agios Pharmaceuticals' Capital Expenditures' 5-year high stood at $4.5 million during Q4 2021, with a 5-year trough of -$22000.0 in Q3 2021.
  • Over the past 5 years, Agios Pharmaceuticals' median Capital Expenditures value was $399000.0 (recorded in 2023), while the average stood at $868526.3.
  • In the last 5 years, Agios Pharmaceuticals' Capital Expenditures crashed by 10042.28% in 2021 and then soared by 536666.67% in 2024.
  • Over the past 5 years, Agios Pharmaceuticals' Capital Expenditures (Quarter) stood at $4.5 million in 2021, then tumbled by 97.49% to $113000.0 in 2022, then surged by 107.08% to $234000.0 in 2023, then soared by 313.25% to $967000.0 in 2024, then soared by 60.81% to $1.6 million in 2025.
  • Its Capital Expenditures stands at $1.6 million for Q3 2025, versus $875000.0 for Q2 2025 and $766000.0 for Q1 2025.